로딩 중…
지수 로딩 중…
Atrium Therapeutics, Inc.
RNA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$11.76-3.21%
2026-07-20
Financials
Valuation Metrics
Atrium Therapeutics, Inc.'s Market Cap is $201M. Ranked #3033 of 3,112 in US market (top 97%), #1376 of 1,443 on NASDAQ (top 95%), #254 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-07-20)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $201M | US#3,033/3,112 Sec#254/269 |
| Revenue | $19M | US#2,920/3,112 Sec#176/269 |
| Net Income | $-77M | US—/3,112 Sec—/269 |
| Total Assets | $278M | US#2,935/3,112 Sec#226/269 |
| Net Assets | $207M | US#2,733/3,112 Sec#198/269 |
| Value | ||
| P/B | 0.97x | US#352/3,112 Sec#15/269 |
| P/S | 10.80x | US#2,695/3,112 Sec#123/269 |
| FCF Yield | -21.16% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -36.99% | US#2,682/3,112 Sec#146/269 |
| ROA | -27.55% | US#2,863/3,112 Sec#154/269 |
| Op. Margin | -412.58% | US#2,901/3,112 Sec#160/269 |
| Financial Health | ||
| Debt Ratio | 34.28% | US#381/3,112 Sec#117/269 |
| Total Debt | $4M | US#2,925/3,112 Sec#231/269 |
| FCF | $-43M | US#2,471/3,112 Sec#110/269 |
| Cash | $270M | US#1,505/3,112 Sec#89/269 |
| Current Ratio | 6.53x | US#363/3,112 Sec#121/269 |
| Performance | ||
| 1M Return | -7.11% | US#2,235/3,112 Sec#222/269 |
| From 52W High | -29.87% | US#2,021/3,112 Sec#169/269 |
| 1Y MDD | -30.17% | US#1,403/3,112 Sec#88/269 |
| Trading | ||
| Volume | 184,991 shares | US#2,854/3,112 Sec#265/269 |
| Trading Value | $2M | US#2,954/3,112 Sec#250/269 |